Sustained release therapeutic for extremity trauma repair

Theradaptive Inc. was awarded a $3,979,465 Project Grant from the Department of the Army Medical Command on September 15, 2022 to complete the project by September 14, 2024. The grant was awarded under the Military Medical Research and Development program (CFDA 12.420), which supports biomedical research to transform military and public health care through innovative solutions for battlefield medicine.

Specifically, the funding will support Theradaptive's development of a sustained release therapeutic for extremity trauma repair. The therapeutic aims to advance treatment options for soldiers suffering orthopedic injuries in combat zones. By developing long-acting medications to regenerate bone and soft tissue, this research could help reduce disability and medical evacuations from the battlefield. The grant enables Theradaptive to conduct the clinical and preclinical studies required to validate their solution over the two year period of performance based in Frederick, Maryland.